ATE509103T1 - Neurotrophe faktoren - Google Patents

Neurotrophe faktoren

Info

Publication number
ATE509103T1
ATE509103T1 AT07120461T AT07120461T ATE509103T1 AT E509103 T1 ATE509103 T1 AT E509103T1 AT 07120461 T AT07120461 T AT 07120461T AT 07120461 T AT07120461 T AT 07120461T AT E509103 T1 ATE509103 T1 AT E509103T1
Authority
AT
Austria
Prior art keywords
neurotrophic factors
neublastin
polypeptides
methods
antibodies
Prior art date
Application number
AT07120461T
Other languages
English (en)
Inventor
Dinah Wen Yee Sah
Teit E Johansen
Anthony Rossomando
Original Assignee
Biogen Idec Inc
Nsgene As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biogen Idec Inc, Nsgene As filed Critical Biogen Idec Inc
Application granted granted Critical
Publication of ATE509103T1 publication Critical patent/ATE509103T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C07K14/4756—Neuregulins, i.e. p185erbB2 ligands, glial growth factor, heregulin, ARIA, neu differentiation factor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Vascular Medicine (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Saccharide Compounds (AREA)
AT07120461T 2001-03-12 2002-03-12 Neurotrophe faktoren ATE509103T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US09/804,615 US20020055467A1 (en) 1998-07-06 2001-03-12 Novel neurotrophic factors

Publications (1)

Publication Number Publication Date
ATE509103T1 true ATE509103T1 (de) 2011-05-15

Family

ID=25189406

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02706759T ATE378353T1 (de) 2001-03-12 2002-03-12 Neurotrophe faktoren
AT07120461T ATE509103T1 (de) 2001-03-12 2002-03-12 Neurotrophe faktoren

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT02706759T ATE378353T1 (de) 2001-03-12 2002-03-12 Neurotrophe faktoren

Country Status (16)

Country Link
US (1) US20020055467A1 (de)
EP (2) EP1373503B1 (de)
JP (2) JP3738008B2 (de)
CN (1) CN1268744C (de)
AT (2) ATE378353T1 (de)
AU (1) AU2002240943B2 (de)
CA (1) CA2440767C (de)
CY (1) CY1111750T1 (de)
DE (1) DE60223511T2 (de)
DK (2) DK1930439T3 (de)
ES (2) ES2366610T3 (de)
HK (1) HK1120556A1 (de)
NZ (1) NZ528790A (de)
PT (2) PT1373503E (de)
SI (2) SI1373503T1 (de)
WO (1) WO2002072826A2 (de)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
DK1640381T3 (da) * 1998-07-14 2014-07-14 Janssen Pharmaceutica Nv Neurotrofisk vækstfaktor
HUP0303900A3 (en) * 2000-12-22 2009-08-28 Genentech Inc New use of artemin, a member of the gdnf ligand family
US7442370B2 (en) * 2001-02-01 2008-10-28 Biogen Idec Ma Inc. Polymer conjugates of mutated neublastin
US7276580B2 (en) * 2001-03-12 2007-10-02 Biogen Idec Ma Inc. Neurotrophic factors
AU2002250203B2 (en) * 2001-03-28 2006-08-10 Biogen Ma Inc. Use of neublastin polypeptides for treating neuropathic pain
JP2005516949A (ja) * 2001-12-19 2005-06-09 リジュン・ワン Ｇｄｎｆの骨格筋へのアデノ随伴ウイルス媒介性のデリバリー
JP4571776B2 (ja) * 2002-11-05 2010-10-27 Ｊｘ日鉱日石エネルギー株式会社 潤滑油組成物
PT2246362E (pt) * 2003-01-31 2014-03-10 Biogen Idec Inc Conjugados de neublastina mutada com polímero
EP2322205A1 (de) 2003-04-18 2011-05-18 Biogen Idec MA Inc. Polymerkonjugiertes glycosiliertes Neublastin
CN100475846C (zh) 2003-06-10 2009-04-08 Ns基因公司 增加的神经胚素分泌
US7598059B2 (en) * 2003-10-02 2009-10-06 Biogen Idec Ma Inc. Neublastin expression constructs
AU2004283053A1 (en) 2003-10-20 2005-05-06 Nsgene A/S In vivo gene therapy of Parkinson's Disease
KR101241551B1 (ko) * 2004-08-19 2013-03-11 바이오겐 아이덱 엠에이 인코포레이티드 전환 성장 인자 베타 패밀리 단백질의 리폴딩
ATE474586T1 (de) * 2004-08-19 2010-08-15 Biogen Idec Inc Neublastin-varianten
EP1937295A2 (de) * 2005-10-11 2008-07-02 NS Gene A/S Behandlung von retinopathien mit gfr3-agonisten
TWI501774B (zh) * 2006-02-27 2015-10-01 Biogen Idec Inc 神經性病症之治療
ES2450065T3 (es) * 2006-03-01 2014-03-21 Biogen Idec Ma Inc. Composiciones y métodos para la administración de proteínas de la familia de ligandos del GDNF
NZ580947A (en) 2007-05-01 2012-05-25 Biogen Idec Inc Compositions and methods for increasing vascularization
US20110135648A1 (en) * 2007-08-08 2011-06-09 Biogen Idec Ma Inc. Anti-neublastin antibodies and uses thereof
US20100247437A1 (en) * 2007-10-01 2010-09-30 Vgx Pharmaceuticals, Llc Materials and methods for the delivery of biomolecules to cells of an organ
CA2813013C (en) * 2010-10-01 2019-10-22 Nsgene A/S Use of meteorin for the treatment of allodynia, hyperalgesia, spontaneous pain and phantom pain
CN112533642A (zh) * 2018-05-17 2021-03-19 赫利世弥斯株式会社 治疗与化疗诱发的周围神经病变相关的神经性疼痛
WO2022244757A1 (ja) 2021-05-18 2022-11-24 株式会社Ｌｔｔバイオファーマ 抗癌剤の投与に伴う障害を治療又は予防するための医薬組成物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6184200B1 (en) * 1995-09-28 2001-02-06 Amgen Inc. Truncated glial cell line-derived neurotrophic factor
CA2253871C (en) 1996-05-08 2005-04-26 Biogen, Inc. Ret ligand (retl) for stimulating neural and renal growth
US6593133B1 (en) * 1998-07-06 2003-07-15 Nsgene A/S Neurotrophic factors
US20020002269A1 (en) * 1998-09-29 2002-01-03 Jeffrey D. Milbrandt Artemin, a neurotrophic factor
AU2354600A (en) * 1998-12-09 2000-06-26 Amgen, Inc. Grnf4 a neurotrophic factor
DK1185648T3 (da) * 1999-06-02 2007-07-30 Genentech Inc Fremgangsmåder og sammensætninger til inhibition af neoplastisk cellevækst

Also Published As

Publication number Publication date
DK1373503T3 (da) 2008-03-25
US20020055467A1 (en) 2002-05-09
NZ528790A (en) 2004-06-25
PT1930439E (pt) 2011-07-25
SI1930439T1 (sl) 2011-09-30
JP3738008B2 (ja) 2006-01-25
AU2002240943B2 (en) 2007-05-10
WO2002072826A2 (en) 2002-09-19
CA2440767A1 (en) 2002-09-19
CN1509333A (zh) 2004-06-30
EP1930439B1 (de) 2011-05-11
AU2002240943A2 (en) 2002-09-24
CA2440767C (en) 2012-05-29
DK1930439T3 (da) 2011-08-29
EP1373503A2 (de) 2004-01-02
DE60223511D1 (de) 2007-12-27
JP2004531242A (ja) 2004-10-14
EP1373503B1 (de) 2007-11-14
DE60223511T2 (de) 2008-10-23
PT1373503E (pt) 2008-02-26
ES2296899T3 (es) 2008-05-01
HK1120556A1 (en) 2009-04-03
CY1111750T1 (el) 2015-10-07
ES2366610T3 (es) 2011-10-21
ATE378353T1 (de) 2007-11-15
EP1930439A1 (de) 2008-06-11
CN1268744C (zh) 2006-08-09
SI1373503T1 (sl) 2008-04-30
WO2002072826A3 (en) 2003-04-10
JP2005198656A (ja) 2005-07-28

Similar Documents

Publication Publication Date Title
CY1111750T1 (el) Νευροτροφικοι παραγοντες
DK1095140T3 (da) Neurotrofe faktorer
DK1434791T3 (da) Specifikke bindingsmidler til human angiopoietin-2
ATE411082T1 (de) Neue verwendung von kurzkettigen carbonsäuren
PT1015585E (pt) Homologos de ligandos de tie
BR0012759A (pt) Neurotoxinas recombinantes ativáveis
EA200400510A1 (ru) Агенты, специфически связывающие ангиопоэтин-2
NO20054836L (no) Nogo-reseptorbindingsprotein
WO2007045019A3 (en) Polyoleosins
ATE309356T1 (de) Konstruierte fluoreszenzproteine mit langen wellenlängen
ATE550345T1 (de) Sfrp, mit sfrp-interagierende peptidmotive sowie verwendungsverfahren
EA200400392A1 (ru) Связывающий каспазу-8 белок, его получение и применение
EA200100110A1 (ru) Нейротрофические факторы
DE60211227D1 (de) Androgenrezeptor-Komplex assoziiertes Protein
WO2001021794A3 (en) Smad associating polypeptides

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1930439

Country of ref document: EP